Correlation Engine 2.0
Clear Search sequence regions

  • alloantibodies (9)
  • antigen (2)
  • blood (4)
  • blood group antigens (2)
  • cats (11)
  • plasma (1)
  • reagent (1)
  • Sizes of these terms reflect their relevance to your search.

    Since the discovery of the Mik antigen, several studies have described blood incompatibilities unrelated to the AB system in cats. To estimate the prevalence of cats with non-AB incompatibilities associated with naturally occurring alloantibodies (NOAb), and to begin mapping the corresponding feline erythrocyte antigens (FEA). Two hundred and fifty-eight type A cats. Prospectively, cats were evaluated for the presence of NOAb by crossmatching in groups of 4-6 cats. When NOAb were detected in a cat, its plasma was used as reagent to assess for the presence of the corresponding FEA in all cats included thereafter, and agreement observed between results of this extensive blood typing was evaluated. The chance of detecting incompatibilities by randomly crossmatching 2 cats was 3.9%, which resulted in at least 7% of type A cats having NOAb. Blood typing and agreement analyses performed with 7 newly detected NOAb allowed the identification of 5 presumably distinct FEA. Feline erythrocyte antigens 1 and 5 were most frequent with prevalence of 84% and 96%, respectively. Only FEA 1-negative status was associated with a higher risk of presenting NOAb; with 16.7% of 42 FEA 1-negative cats having NOAb compared to 5.1% of 216 FEA 1-positive cats. This study represents a first step of FEA identification outside the AB system. Because of its prevalence and association with NOAb, FEA 1 might correspond to the Mik antigen. © 2020 The Authors. Journal of Veterinary Internal Medicine published by Wiley Periodicals LLC. on behalf of the American College of Veterinary Internal Medicine.


    Marie Binvel, Julie Arsenault, Boris Depré, Marie-Claude Blais. Identification of 5 novel feline erythrocyte antigens based on the presence of naturally occurring alloantibodies. Journal of veterinary internal medicine. 2021 Jan;35(1):234-244

    Expand section icon Mesh Tags

    Expand section icon Substances

    PMID: 33336860

    View Full Text